People

The People

Governance grade: C+. Blue Moon is a family-controlled founder business where the husband–wife co-founder duo (Chairman PAN Dong + CEO LUO Qiuping) own roughly 76% of the shares. Alignment on paper is maximal, but independence is at the Hong Kong Listing Rules floor, minority voice is thin, and the public float has quietly concentrated below the default 25% — prompting the Company in January 2026 to adopt HKEX's Rule 13.32B alternative threshold. Balance-sheet stewardship (net cash, non-dilutive share awards, zero borrowings) is the redeeming story.

Governance Grade

C+

Founder-Family Stake (%)

76.0

Board Independence (%)

37.5

Public Free Float (%)

21.15

The People Running This Company

Blue Moon has no professional-CEO layer separating the founder family from operations. The Chairman and the CEO are husband and wife, both are co-founders, and between them they also hold the Chief Technology Officer and COO-adjacent roles. A third Luo (LUO Dong) also sits on the Executive Directors' bench, so the executive board is effectively five names of whom at least three are family-adjacent insiders.

No Results

**Family-density risk.** Three of the five executive directors share bloodlines or marriage ties (PAN Dong, LUO Qiuping, LUO Dong). Succession planning is not disclosed; the CEO is 62 and the Chairman is 60. An unexpected departure would concentrate operational authority on POON (CFO) and XIAO (COO) — neither of whom has a public track record outside Blue Moon.

What They Get Paid

Per-director cash-and-incentive emoluments are published in the full Annual Report under HKEX Appendix C1 — the March 2026 results announcement does not repeat them. What is disclosed is the overall employee cost envelope (down 6.4% year-on-year as losses narrowed) and the share-plan mechanics, which are the compensation items that actually matter for shareholders. Pay signal is therefore legible through the share plans and the auditor-fee ratio, not through a CEO-pay table.

No Results

**Non-dilutive incentive design.** Both share-award plans are satisfied out of *existing* shares purchased in the open market, not newly issued stock. That makes Blue Moon's ~396m cumulative share grants (6.8% of shares outstanding) effectively a return-of-capital mechanism rather than a dilutive drain on minority economics. This is one of the cleanest shareholder-friendly pay designs in the HKEX consumer-staples space.

The audit-fee ratio also tells a small but useful story. Non-audit fees to auditor PricewaterhouseCoopers fell from HK$2.107m (FY2024) to HK$1.102m (FY2025), cutting the non-audit-to-audit ratio from 61% to 31% — moving toward auditor-independence best practice rather than away from it. Audit cost itself ticked up just 2% to HK$3.56m (~$0.46m), proportionate to an HK$8.4B-revenue consumer-products business.

Are They Aligned?

This is where Blue Moon's grade earns its asterisks. Economic alignment is textbook — the founder family has roughly $1.7B of personal market value on the tape — but control alignment sits in tension with minority alignment on three specific axes: free-float shrinkage, option-exercise optics, and the dividend-vs-losses debate.

**Float concentration decision — 8 January 2026.** The Company adopted HKEX Rule 13.32B's alternative free-float threshold (market cap of at least HK$1bn AND at least 10% public hands), replacing the default 25% minimum. This is a concession to a shrinking public register and functionally locks in minority dilution of voting influence. The move is legal and disclosed, but it is the single strongest signal that the founder family intends to keep control tight — not broaden ownership.

Option exercise and insider dealing. During FY2025, 987,850 share options were exercised at a weighted-average price of HK$3.76 (FY2024: 110,000) — against a share price that spent most of the year between HK$2.50 and HK$4.34. That is in-the-money exercise behaviour in the upper half of the trading range, suggesting participants exercised into strength rather than distress. Aggregate-only disclosure in the results announcement masks which directors exercised; the detailed Directors' Interests notifications on HKEXnews would close that gap. No company or subsidiary buybacks of listed securities occurred in FY2025.

Related-party transactions. The balance sheet shows just HK$412,000 (~$53,000) due to a related company at 31 December 2025 — essentially a rounding error in an HK$9.35B balance sheet. This is unusually clean for a Chinese family-controlled issuer, where related-party bloat is a standard concern. Credit where due.

Capital-allocation posture. FY2025 still printed an HK$312m net loss, yet the Board resumed the dividend (HK8 cents interim + HK10 cents final = HK18 cents total, a 6.08% trailing yield). With HK$4.88B net cash and zero borrowings, paying out from accumulated reserves is defensible — but it is worth naming: the founder family receives roughly 76% of that dividend, making this simultaneously a pro-minority cash return and a pro-founder wealth-preservation move.

Skin-in-the-Game Score (1-10)

Board Quality

No Results

**Independence is at the Code floor.** Three of eight directors (37.5%) are classified Independent Non-Executive — one-third is the HKEX minimum. Investor-grade boards in consumer staples typically run at 50% or more independence. The board structure legally clears the bar but offers very limited counter-weight against a 76%-owner Chairman. Committee memberships (Audit / Remuneration / Nomination) are disclosed only in the full Annual Report, not in the results announcement reviewed here.

Auditor and compliance hygiene. PricewaterhouseCoopers has signed the accounts; the audit-vs-non-audit fee ratio improved materially in FY2025 (see pay section). All directors confirmed Model Code compliance. The company self-assesses as fully compliant with Appendix C1 of the HKEX Corporate Governance Code. The Chamber of Hong Kong Listed Companies granted Blue Moon a Corporate Governance Excellence Award for 2024-2025 and an ESG Honourable Mention in 2025 — modest positive third-party validation.

Missing capability. The disclosed skill distribution across the INEDs (based on the results announcement — full AR bios would add colour) is thin on publicly named capital-markets or M&A expertise. For an HK$17.3B-market-cap consumer-staples issuer with HK$4.9B of excess cash, the capital-allocation committee muscle is concentrated inside the executive bench, not checked by an outside voice.

The Verdict

Governance Grade

C+

Why C+ and not B. The positives are real: ~76% founder economic stake, non-dilutive share-award design, de minimis related-party exposure, net-cash balance sheet, clean auditor relationship, resumed dividend. These are the markers of a founder who still treats the business as personal wealth rather than a vehicle for extraction. Blue Moon avoids most of the specific pathologies that earn Chinese HKEX-listed consumer companies a D or F.

Why not B+ or higher. Four items keep the grade capped: (1) a husband–wife executive chairman/CEO pair removes the practical chairman-CEO separation that exists on paper; (2) a third executive director shares the CEO's surname with no disclosed independence test; (3) the public free float has drifted below the 25% default, triggering the Rule 13.32B alternative-threshold adoption in January 2026 — a defensive governance choice, not an expansive one; (4) INED headcount sits exactly at the Listing Rule floor rather than at investor-grade best practice.

What would move the grade. Upgrade catalysts: (a) a fourth INED with disclosed capital-markets or consumer-M&A expertise; (b) per-director pay disclosure adopted pre-full-AR; (c) a buyback program of listed securities (not just share-plan market purchases) signalling capital-allocation discipline to minorities. Downgrade catalysts: (a) any enlargement of the related-party line, however modest; (b) insider exits above the 987,850-option-exercise scale without offsetting reinvestment; (c) further shrinkage of the public float toward the 10% Rule 13.32B floor.